Effectiveness of 14-Days Course of Clarithromycin-Based Triple Therapy as First Line Therapy for h.pylori Infection in Egyptian Elderly

2015 ◽  
Vol 2 (1) ◽  
pp. 19-26
Author(s):  
Salamah A. M. ◽  
Gad M. ◽  
Deghady A.
Keyword(s):  
Triple Therapy ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Is It Time for Quadruple Therapy to be First Line?

2003 ◽  
Vol 17 (suppl b) ◽  
pp. 33B-35B ◽  
Author(s):  
Loren Laine
Keyword(s):  
Triple Therapy ◽  
Randomized Trials ◽  
Eradication Rate ◽  
First Line ◽  
Quadruple Therapy ◽  
First Line Therapy ◽  
Clarithromycin Resistance ◽  
Line Therapy ◽  
Metronidazole Resistance ◽  
H Pylori

The most commonly used regimen forHelicobacter pyloritherapy at present is twice-daily proton pump inhibitor (PPI)-based triple therapy. Bismuth-based therapy is the next most common treatment used by gastroenterologists. When a PPI is combined with bismuth-based triple therapy (quadruple therapy), eradication rates are increased as compared with the triple therapy alone. Three separate randomized trials from three continents that compare quadruple therapy and PPIbased triple therapy revealed remarkably similar results. Eradication rates with PPI-based triple therapy and quadruple therapy were not significantly different. The eradication rates with quadruple therapy were 3% to 6% higher than PPI triple therapy, indicating that quadruple therapy should be no less effective than PPI triple therapy. Furthermore, these two therapies had similar rates of compliance and adverse events.The major potential benefit of the quadruple therapy relates to antibiotic resistance. In patients with clarithromycin resistance, PPIbased triple therapy, but not quadruple therapy, had a significantly lower eradication rate. However, due to its ability to largely overcome metronidazole resistance, quadruple therapy had little if any decrement in eradication rates compared with PPI triple therapy in patients with metronidazole-resistantH pylori. Therefore, quadruple therapy can be considered a first line therapy forH pylori.

Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy forHelicobacter pylorieradication

2014 ◽  
Vol 23 (5) ◽  
pp. 443-455 ◽  
Author(s):  
Chen-Li Ye ◽  
Guo-Ping Liao ◽  
Shuai He ◽  
Yan-Na Pan ◽  
Ying-Bo Kang ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Triple Therapy ◽  
Proton Pump ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Eradication Rates of Clarithromycin Triple Therapy in Korea: A Systematic Review and Meta-analysis

2021 ◽  
Vol 21 (1) ◽  
pp. 35-47
Author(s):  
Seung Joo Kang ◽  
Hye-Kyung Jung ◽  
Yong Chan Lee ◽  
Hyo-Joon Yang ◽  
Seon-Young Park ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Eradication Rate ◽  
Meta Analysis ◽  
Random Effect ◽  
Cochrane Library ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Randomized Controlled Studies ◽  
Standard Triple Therapy

Background/Aims: Standard triple therapy, including a proton pump inhibitor, clarithromycin, and amoxicillin, has been recommended as the first-line for <i>Helicobacter pylori</i> infection. However, the eradication rate of standard triple therapy has declined over the past years because of the increasing resistance to clarithromycin in Korea. We analyzed the eradication rates and the 10-year change in the eradication rates in Korea.Methods: PubMed, EMBASE, the Cochrane Library, and KoreaMed were searched for studies published between January 2007 and June 2018. The pooled eradication rates and their 95% CIs were estimated using a random-effect logistic regression model.Results: Twenty-six randomized controlled studies on standard triple therapy conducted in Korea were selected. The intention-to-treat (ITT) and per protocol analyses showed pooled eradication rates of standard triple therapy of 71.6% (95% CI, 69.9~73.3%) and 79.6% (95% CI, 76.6~82.2%), respectively. The eradication rate decreased with time. The ITT analysis showed that the 14-day therapy (78.1% [95% CI, 75.2~80.7%]) had significantly higher eradication rates than the 7-day therapy (70.0% [95% CI, 68.5~71.4%]) (<i>P</i><0.01).Conclusions: These results suggest that the eradication rate of standard triple therapy, as the first-line therapy, has shown an unacceptable decrease. The eradication rate increased when the duration of therapy was increased to 14 days, but it was not satisfactory. Therefore, other treatment regimens or therapies based on susceptibility tests should be considered for the first-line therapy.

1904: Outcomes of Large Renal Calculi (>2-Cm) Treated with ESWL as First Line Therapy

2004 ◽  
Vol 171 (4S) ◽  
pp. 503-503
Author(s):  
Richard Vanlangendock ◽  
Ramakrishna Venkatesh ◽  
Jamil Rehman ◽  
Chandra P. Sundaram ◽  
Jaime Landman
Keyword(s):  
Renal Calculi ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document